Encompass Health (EHC) Q2 2026 earnings review
Aggressive Expansion Yields Strong Beat and Raise
Encompass Health delivered a robust Q2 2026, accelerating top-line growth to 9.6% ($1.6B) and driving a 10.7% increase in Adjusted EPS. The underlying engine—unmet market demand fueled by aging demographics—is allowing EHC to rapidly deploy new capacity while maintaining high occupancy. Strong labor cost containment pushed Adjusted EBITDA up 9.2%. Management capitalized on the momentum by raising full-year guidance across all metrics and aggressively increasing the share repurchase authorization to $1 billion.
🐂 Bull Case
EHC added 139 de novo beds and 54 existing hospital beds in H1 2026. With 5 more hospitals expected before year-end and a new small-format chassis rolling out in 2027, the company is successfully capturing unmet market demand.
Salaries and benefits fell to 51.4% of revenue in Q2 2026, down from 52.7% a year ago. EHC's centralized talent acquisition and career ladders have structurally suppressed premium labor reliance.
🐻 Bear Case
High baseline occupancy rates (77.4% in Q2) place a functional ceiling on same-store volume growth, making the company highly dependent on CapEx-heavy de novo and bed addition projects.
Medicare Advantage plans continue aggressive utilization management, forcing administrative burdens like EHC's 'admit and appeal' strategy. Simultaneously, CMS is rolling out the TEAM bundled payment model and RCD reviews.
⚖️ Verdict: 🟢
Bullish. EHC pairs a highly visible secular growth runway (aging demographics) with exceptional operational execution. The dual strategy of aggressive capacity expansion and a $1B buyback authorization creates a compelling total return profile.
Key Themes
Aggressive Capacity Expansion
Accelerating. EHC is successfully executing a multi-pronged development strategy. In Q2 alone, the company opened a 50-bed hospital in PA and a 40-bed facility in GA, while adding 10 beds to existing locations. Management confirmed plans to open 5 additional hospitals and over 100 existing beds before year-end, validating the robust de novo pipeline and high ROIC on facility expansions.
Structural Labor Cost Containment
Stable. The company continues to lap the post-pandemic labor crisis with excellent cost discipline. Salaries and benefits as a percentage of net operating revenue improved 130 basis points YoY to 51.4%. This structural margin defense is driven by record-low RN turnover and minimal reliance on expensive contract labor, maximizing operating leverage as revenues scale.
Demographic Tailwinds & Volume Growth
Stable. The macro picture remains the core driver. Discharge volumes grew a healthy 5.6% in Q2, split evenly between new-store and same-store growth (2.8% each). The aging population—specifically the 75+ cohort growing at ~4% annually—ensures robust baseline demand for EHC's stroke, neurological, and physical rehabilitation services.
Same-Store Occupancy Constraints
Stable. Despite high overall demand, organic growth faces a physical ceiling. Q2 occupancy sat at a high 77.4% (following 78.7% in Q1). Because many facilities are functionally capped above 85-90% occupancy, EHC's same-store discharge growth has decelerated from the mid-4% range a year ago to 2.8% today. Future volume is heavily reliant on timely construction execution.
Free Cash Flow Divergence
Reversing. While Adjusted EBITDA grew 9.2%, Adjusted Free Cash Flow actually declined 4.8% YoY in Q2 to $177.0M (down from $185.9M). This contradicts the strong margin narrative and was driven by higher maintenance CapEx ($66.2M vs $45.1M in Q2 25) and working capital timing. If capacity expansion costs accelerate faster than collections, cash flow conversion could remain pressured.
Regulatory & Payer Friction
Stable. The broader macro regulatory environment remains a point of friction. CMS is advancing the Review Choice Demonstration (RCD) in massive markets like Texas (started March 2026) and California (May 2026). Simultaneously, Medicare Advantage (MA) plans, which represent 16.2% of Q2 revenue, continue aggressive utilization management, forcing EHC to scale an administrative 'admit and appeal' strategy.
Small-Format Hospital Innovation
EHC is introducing a new product class to circumvent expansion bottlenecks: the 20-30 bed 'small-format hospital'. Scheduled for its first opening in 2027, this chassis requires only 2-3 acres and functions as a remote hub-and-spoke location to an existing larger hospital. This allows EHC to penetrate landlocked or highly saturated markets without the administrative overhead of standalone licensing.
Other KPIs
Stable. The balance sheet remains in pristine condition. During the quarter, the company actively managed its maturity profile by issuing $500M of 5.875% notes due 2034 to redeem $400M of 4.5% notes due 2028. This provides massive flexibility for both CapEx and buybacks.
Accelerating. The company aggressively bought back 703,877 shares in Q2, bringing the YTD total to $145.8M. More importantly, the Board approved a massive increase in the repurchase authorization to $1 billion in July 2026, signaling management's belief that shares remain undervalued relative to the cash generation capability.
Guidance
Accelerating. Management raised the range from the previous $6,375–$6,470M. The midpoint of $6,450M implies an 8.7% YoY growth rate over FY25's $5,935M, reflecting confidence in back-half pricing and capacity additions.
Accelerating. Raised from the prior $1,350–$1,380M range. The midpoint of $1,380M represents an 8.8% growth over FY25. EHC expects to maintain its ~21.4% margin profile despite the drag of pre-opening costs for new hospitals.
Accelerating. A significant bump from the previous $5.89–$6.11 guide. The midpoint ($6.135) suggests massive 12.6% YoY growth compared to FY25 ($5.45), heavily supported by the aggressive share repurchase program reducing the denominator.
Key Questions
Admit and Appeal Scalability
With Medicare Advantage utilization pressure ongoing, what are the early success rates of the 'admit and appeal' pilot strategy, and how significantly will administrative costs rise as you scale this across more markets?
Small-Format Unit Economics
As we approach the 2027 rollout of the small-format chassis, how do the expected Return on Invested Capital (ROIC) and ramp-to-maturity timelines compare to a traditional 50-bed de novo facility?
California and Texas RCD Impact
With the Review Choice Demonstration fully rolling out in Texas and California this spring, are you seeing any elevated initial denial rates or delayed cash collections compared to your historical experience in Pennsylvania or Alabama?